Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study

BACKGROUND: Neutralizing monoclonal antibody (MAB) therapies may benefit patients with mild to moderate COVID-19 at high risk for progressing to severe COVID-19 or hospitalization. Studies documenting approaches to deliver MAB infusions and demonstrating their efficacy are lacking. OBJECTIVE: We des...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarrett, Mark, Licht, Warren, Bock, Kevin, Brown, Zenobia, Hirsch, Jamie, Coppa, Kevin, Brar, Rajdeep, Bello, Stephen, Nash, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477905/
https://www.ncbi.nlm.nih.gov/pubmed/34606522
http://dx.doi.org/10.2196/29638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477905/
https://www.ncbi.nlm.nih.gov/pubmed/34606522
http://dx.doi.org/10.2196/29638

Ejemplares similares